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The phosphatidylinositol 3-kinase (PI3K)/Akt/mammaliantarget of rapamycin (mTOR) pathway plays a critical role
in cell signaling, regulating pivotal cellular functions such as
transcription, translation, and cellular metabolism, in addition
to controlling cell growth and proliferation. Any aberration to
this pathway can disrupt the key balance between cellular
survival and programmed cell death, ultimately leading to
tumorigenesis. Constitutive activation of the PI3K/Akt/
mTOR pathway has been described in a vast array of cancer
types, including non-small cell lung cancer (NSCLC), mak-
ing it an attractive target for novel anticancer agents.
The PI3K/Akt/mTOR pathway is commonly up-regu-
lated in NSCLC with frequent expression of phosphorylated
Akt, mTOR, 4E-BP1, and p70 s6K in tumor tissue. Phos-
phorylation of Akt at the Ser473 and Thr308 sites occurs in
more than 70% of NSCLC tumors and is linked to shorter
overall survival.1 Furthermore, overexpression of pAkt (41%)
and PTEN loss (46%) seems to confer poor prognosis in
NSCLC.2 Finally, activation of the PI3K/Akt/mTOR pathway
has been implicated in tobacco carcinogen-induced cellular
transformation, tumor invasion, and resistance to therapy in
NSCLC.3–5 Herein, we describe recent developments and
future directions in the targeting of this pathway in lung
cancer, presented at the 11th Annual Targeted Therapies of
the Treatment of Lung Cancer Symposium.
mTOR Inhibition
The mTOR pathway plays a key role in cell prolifera-
tion by coupling cell growth with G1-S progression. Inhibi-
tors of this pathway include the macrolide rapamycin (siroli-
mus) and its derivatives temsirolimus (CCI-779) and
everolimus (RAD-001) which induce cell cycle arrest in G1.
Sirolimus is an oral rapalog that inhibits mTOR by
binding to the FK506 binding protein. Preclinical models
have suggested synergy with sirolimus combined with
pemetrexed, as aminoimidazolecarboxamide ribonucle-
otide formyltransferase, the downstream target of pemetrexed,
also inhibits mTOR activity through increased cellular amino-
imidazolecarboxamide ribonucleotide (ZMP). Sirolimus has
been combined with pemetrexed in a phase I dose-escalating
study in platinum-resistant/refractory NSCLC.6 Pemetrexed
(375–500 mg/m2) was administered intravenously on a 3
weekly schedule with once daily oral administration of sirolimus
(1–5 mg). Treatment was well tolerated with no dose-limiting
toxicities observed. Of the 13 evaluable patients, three had a partial
response (PR) and two had minor responses (MR). A phase II
portion of this study is ongoing and incorporates pharmacodynamic
sampling before and after treatment to establishmTORactivation as
a potential predictive marker.
Everolimus has shown antitumor activity in NSCLC
both as a single agent and in combination with other antican-
cer agents. Dr. Khuri (Winship Cancer Institute) discussed
the current phase IB study of everolimus in operable NSCLC.
After an initial tumor biopsy, eligible NSCLC patients were
treated with everolimus 5 to 10 mg/d for 3 weeks before
surgical resection. Positron emission tomography (PET)
scans were performed before and after therapy. Reductions in
SUV were noted in 8 of 17 patients enrolled to date (14
treatment, 3 controls), suggesting biological activity for this
agent as monotherapy in NSCLC.
Dr. Papadimitrakopoulou (MD Anderson Cancer Cen-
tre) discussed the findings of a phase II study which evaluated
the efficacy of everolimus 10 mg once daily in patients with
advanced NSCLC who progressed after 2 prior chemother-
apy regimens.7 A total of 85 patients were enrolled and
stratified into two cohorts according to prior treatments re-
ceived (chemotherapy only versus chemotherapy and EGFR
inhibitor). Treatment was generally well tolerated with more
commonly reported side effects including mucositis, fatigue, and
gastrointestinal disturbances. Partial responses were observed in
7 and 2% of patients in the two cohorts, respectively, confirming
activity for this agent as monotherapy in NSCLC.
Everolimus has demonstrated synergistic interaction
when combined with cytotoxics and EGFR inhibitors in vitro,
leading recent clinical trials to focus on the efficacy of these
combinations in NSCLC. Dr. Kris (Memorial Sloan Ketter-
ing) discussed the findings of a phase II study of everolimus
in combination with gefitinib in advanced NSCLC.8 The
study was enriched for patients likely to have EGFR wild-
type tumors, enrolling current or former smokers only. A total
of 62 stage IIIB/IV NSCLC patients were enrolled with equal
number of previously treated and chemotherapy-naive pa-
tients. Partial responses were seen in 8 of 62 patients (13%)
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with five of the responders being chemotherapy naive. EGFR
mutations were identified in the tumors of three patients with
PR. Unexpectedly, both patients with tumors harboring a
KRAS (G12F) mutation responded to the combination. Over-
all, however, the observed response rate fell short of the
prespecified threshold of 16% required to progress to the
second phase of the study. Finally, several clinical trials
evaluating the efficacy of everolimus in combination with
chemotherapy are ongoing with promising early results from
a phase II study of everolimus and pemetrexed in the second-
line treatment of advanced NSCLC.
Temsirolimus is an ester of sirolimus. As monotherapy,
it has limited activity in lung cancer; however, there is
preclinical rationale for increased efficacy when combined
with other anticancer agents. Dr. Reckamp (City of Hope and
Beckman Research Institute) summarized the results of five
phase I studies which evaluated temsirolimus in combination
with chemotherapy in solid tumor patients. There was a
suggestion of clinical activity in one study which used carbo-
platin and paclitaxel as the chemotherapy regimen of choice
reporting PR in 39% and SD in 46% of the 31 patients treated.9
Similarly, other phase I combination studies have also suggested
increased activity for temsirolimus when combined with EGFR
tyrosine kinase inhibitors, vascular endothelial growth factor
(VEGF) inhibitors, and VEGF receptor inhibitors.
PI3K Inhibition
In vivo experiments suggest that inhibition of the PI3K
pathway can impair tumor cell growth and proliferation and
sensitize cells to programmed cell death. Dr. Khuri (Winship
Cancer Institute) summarized recently presented clinical data
relating to four different PI3 kinase inhibitors. In total, 180
patients were treated with PI3K inhibitors in these studies.
Treatment was generally well tolerated with responses seen in
five patients. Disease stabilization was observed in NSCLC,
mesothelioma, prostate, and colon cancer.
Dr. Jimeno (University of Colarado Cancer Center)
discussed the findings of a phase I study evaluating PX-866,
the only irreversible pan-inhibitor of class IA and B PI3
kinase.10 Seventy-one solid tumor patients were enrolled in
this dose-escalation study evaluating an intermittent (once
daily on days 1–5 and 8–12 of a 28-day cycle) and continu-
ous (days 1–28) schedule for this oral compound. PX-866
was generally well tolerated. The mean tolerated dose (MTD)
was 12 mg/d for the intermittent schedule and 8 mg/d for the
continuous schedule. Overall, the continuous schedule
seemed to have similar safety but better disease control than the
intermittent schedule. Studies combining PX-866 with docetaxel
(phase I/II) and cetuximab (phase II) have been initiated, while
two single-agent phase II studies of PX-866 in castration-resis-
tant prostate cancer and glioblastoma are planned.
BKM 120 is an oral pan-class I PI3K inhibitor. A phase
I dose-escalation study evaluating BKM 120 (12.5–150 mg)
in 30 solid tumor patients established the MTD as 100 mg
once daily.11 Clinical activity for this agent was evidenced by
8 of 10 patients treated at 100 mg having metabolic PR by
FDG-PET, with 1 PR and 5 MR by RECIST. Finally, disease
stabilization for more than 4 months was observed in 12
patients treated across all doses.
Data relating to BEZ235, a first-in-class dual PI3K and
mTOR inhibitor, were presented by Dr. Spigel (Sarah Cannon
Research Institute). This compound is a potent, highly selec-
tive, and reversible inhibitor of the PI3K pathway which has
shown antiproliferative and apoptotic activity in vivo. It acts
by binding to the ATP-binding cleft of the p110a subunit of
PI3K (mutant and nonmutant forms), and mTOR complexes
1 and 2. A phase I dose-escalation study of BEZ235 was
conducted in 59 advanced solid tumors patients.12 BEZ235
demonstrated dose-dependent PI3K inhibition measured by
elevation of plasma C-peptide levels. The compound was
generally well tolerated with no dose-limiting toxicities ob-
served. Two patients had PR, 16 had MR, whereas stabiliza-
tion of disease for more than 4 months was observed in 14 of
51 (27%) evaluable patients. Finally, reduction in 18-FDG
uptake on PET imaging was noted in 18 of 35 (51%) evalu-
able patients.
BAY 80-6946 is a potent and highly selective pan class
I intravenous PI3K inhibitor. It has shown synergistic activity
with the MEK inhibitor BAY 86-9766 in vivo and with
gemcitabine and paclitaxel in NSCLC mouse models. Dr.
Adjei (Roswell Park Cancer Institute) discussed an ongoing
phase I dose-escalation study of BAY 80-6946 administered
intravenously (days 1, 8, and 15 of a 28-day cycle) in patients
with advanced cancer. Several correlative biomarker studies
are planned, and preliminary results will soon be presented.
AKT Inhibition
Akt activation has been implicated in the development
of resistance to anticancer agents, including EGFR tyrosine
kinase inhibitors. Thus, combining EGFR TKIs with selective
Akt inhibitors may increase antitumor activity and impair the
development of EGFR TKI resistance.
MK 2206 is an orally active, highly potent, and selec-
tive allosteric Akt inhibitor. A phase I dose-escalation study
of MK 2206, conducted in 19 solid tumor patients, estab-
lished a maximum tolerated dose of 60 mg once daily for this
agent.13 Biological activity for MK 2206 was seen with
reductions in pAkt levels measured in whole blood and
observed elevations in insulin c-peptide levels. Stable disease
by RECIST after two cycles of therapy was observed in one
patient treated at 30 mg and five patients at 60 mg.
MK 2206 has shown synergistic antitumor activity
when combined with erlotinib in both KRAS/EGFR wild-
type and EGFR-mutant NSCLC models. This activity is
mediated in part through the ability of MK2066 to reverse
hepatocyte growth factor (HGF)-induced resistance to erlo-
tinib. A phase II clinical study is planned to evaluate the
combination of MK 2206 and erlotinib in patients with
advanced NSCLC with previous response and subsequent
progression on erlotinib. Patients will be stratified by EGFR
mutation status and will receive erlotinib once daily and MK
2206 on alternate days. Collection of tumor tissue will allow
for correlative studies to evaluate Akt pathway inhibition.
Chromatin Remodeling
The SWI/SNF chromatin remodeling complex regu-
lates the transcription of several genes by controlling chro-
matin structure in an ATP-dependent manner. There is in-
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creasing evidence that this complex plays an important role in
suppressing the development of cancer. Dr. Gazdar (UT
Southwestern) presented the findings of a comprehensive
study of all 20 gene members of this complex in NSCLC,
which focused on gene expression, frequency of mutations
and allelic loss, and protein expression and methylation.
There was widespread deregulation of the SWI/SNF chroma-
tin remodeling complex involving approximately half of all
gene members, including the LKB1 tumor-suppressor gene
which inhibits proliferation and invasion through the mTOR
pathway. Overall, up to 10% of the transcriptome is predicted
to be affected by the deregulation, providing multiple oppor-
tunities for potential targeted therapies.
Future Directions
The PI3K/Akt/mTOR pathway is increasingly recog-
nized as an important therapeutic target in NSCLC with
encouraging results from early clinical studies evaluating
these novel agents. Dual blockade of the deregulated signal-
ing pathway seems particularly promising with the capacity
to overcome the Akt-mediated resistance observed with pro-
longed rapalog or EGFR inhibitor monotherapy. Improved
understanding of the biology and signal circuitry underlying
the PI3K/Akt/mTOR pathway in NSCLC will enable mech-
anism-based novel combinations of these agents in future
studies. Finally, it is imperative that we better identify those
patients most likely to respond to therapy targeting the
PI3K/Akt/mTOR pathway. Efforts should be made to incor-
porate pharmacodynamic sampling routinely into future clin-
ical trials with the aim of identifying reliable predictive
markers for therapy.
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